List of Immuno-Assays Companies in Massachusetts - 8

BioPAL is a biotechnology company that provides novel diagnostic tools to the life science community.

Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology.

At Meadowhawk we recognize that the standard, cookie-cutter approach to CRO services is rarely the best option for any individual client or program. So rather than ask our clients to compromise for us we provide CRO services with flexible, fit-for-purpose study designs to deliver high quality data as quickly as possible. Offering a range of non-GLP services, our experts collaborate with you to find the right solutions for your study providing a single-point-of-contact to streamline communication.

MeMed is a leading med tech and bio-convergence company, having developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders – at the right place and the right time.

NeuroDex is developing a suite of blood-based biomarkers that can identify patients with synucleinopathies even in the context of different forms of dementia. This technology relies on NeuroDex’s recent advances in isolatingcell-specific extracellular vesicles (exosomes) from plasma and detecting protein markers of disease in the contents or on the surface of NDEs. Extracellular vesicles/exosomes are nano-sized (30-200nm) membrane vesicles released from all cell types in the body. While the biogenesis and biological function of extracellular vesicles are complex, it is clear that they carry protein, RNA, and lipids that reflect their cell of origin and thus can serve as a rich source of biomarkers.

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company's ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio.

Stata DX is a developer of a disease management eRapid technology designed to implement custom biomarker panels for clinical studies.